RNA drugs are a new type of biotechnology drug, whose core is to use synthesized mRNA molecules to transmit specific genetic information to promote the production of specific proteins in cells. During the preparation of these mRNA drugs, double stranded RNA (dsRNA) residues are often generated, which may trigger adverse immune reactions or potential cytotoxicity. Therefore, it is crucial to avoid the production of dsRNA as much as possible in mRNA sequence design and optimization, remove dsRNA residues during mRNA purification, and detect dsRNA residues after purification to ensure quality control in the production process and the safety and effectiveness of the final drug product. At present, the industry generally uses ELISA and other methods to detect residual dsRNA, but there is a lack of in-depth understanding and research on the sequence types and characteristics of dsRNA itself.

GentleGen has launched a unique and innovative IVT mRNA dsRNA residue analysis and detection method in the industry, which utilizes emerging high-throughput sequencing technology (NGS) combined with a self-developed bioinformatics analysis process to analyze the hotspots of dsRNA production in in in vitro transcribed mRNA, assisting in mRNA sequence design optimization and improvement, and reducing the production of dsRNA. GentleGen is committed to promoting the application of emerging technologies such as high-throughput sequencing in the quality and safety evaluation of biomedicine, accelerating the research and application of nucleic acid drugs.